Flywheel, the leading cloud-based data management platform for biomedical research and collaboration, today announced the closure of its Series C funding round including an investment from Intuitive Ventures, a venture capital fund dedicated to advancing the future of minimally invasive care and beyond. This brings Flywheel’s Series C round to a total of $27.5 million. 

Imbio, a medical imaging artificial intelligence (AI) provider for chronic lung and cardiothoracic diseases, and MEDICAL-NOTE, an applications and software company for surgical procedure management and multi-disciplinary team communication, announced they are partnering to expand access to Imbio AI technologies across Italy.

Invenshure announces today that Flywheel has acquired Radiologics. Together, the two companies, now operating as Flywheel, offer the only biomedical research platform capable of connecting any organization or data set across life sciences, academia, clinical, and medical AI.

Financing Led by Casdin Capital with Participation from Leading Life Sciences Investors.

Flywheel, the leading data management platform for medical research and collaboration, today announced a partnership and enterprise license agreement with Siemens Healthineers.

Flywheel, the leading cloud-scale informatics platform for medical research and collaboration, and HealthMyne, a pioneer in applied radiomics, announced today a partnership that will combine the companies’ technologies to accelerate radiomics research and advance clinical trials outcomes for life sciences and clinical research clients.

Imbio, a leading medical imaging artificial intelligence (AI) provider for chronic lung and cardiothoracic diseases, and Riverain Technologies™, a leader in clinical AI for lung nodules, announce a partnership to deliver a more complete lung health solution for clinicians, health systems, and radiology practices through a joint offering of their FDA cleared AI tools.

Exosite LLC, a leading provider in the Industrial Internet of Things (IIoT) platform market, today announced a new partnership with Eurotech, a company that designs, develops and deploys IoT hardware, software, services and solutions.

GeneMatters, a leading provider of telegenetics services and software, and Concert Genetics, a healthcare technology company providing the digital infrastructure for genetic testing management, today announced a partnership to help healthcare systems meet patient demand for high-quality, personalized clinical genetics services.

Imbio, a leading provider of artificial intelligence (AI) solutions for medical imaging analysis, has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its RV/LV Analysis™ algorithm.

AI-based Software Providing Physicians with Quantitative Evaluation of CT Scans (QCT) for the Non-invasive Determination of Patient Eligibility for the Spiration Valve System Procedure to Treat Severe Emphysema

GeneMatters today announced significant advancements to their proprietary integrative software, now known as the Pioneer Telegenetics Platform™, as well as the launch of RISE Patient Engagement Tools™.

​In March, Imbio, an AI-driven medical imaging company that specializes in lung analysis, partnered with the Flywheel Exchange and their parent company Invenshure, combining their technologies to empower researchers to better aggregate and analyze COVID-19 related data

MINNEAPOLIS, Oct. 27, 2020 /PRNewswire/ -- Imbio, a healthcare technology company developing the leading suite of medical image analysis for pulmonary and cardiothoracic diseases, and Siemens Healthineers, a leading medical technology company, announced they are partnering to expand access to Imbio AI algorithms worldwide.

The partnership will provide a scalable solution for improved patient management and the delivery of accurate data for oncology research.

MINNEAPOLIS, Oct. 6, 2020 /PRNewswire/ -- Imbio, a leading provider of artificial intelligence (AI) solutions for medical imaging analysis, has partnered with Genentech, a member of the Roche Group, to develop quantitative imaging diagnostics for lung diseases. The multi-year agreement leverages Imbio's technical, regulatory and commercial expertise to build and deploy medical imaging AI technology for use in research, clinical trials, and clinical practice.